Gene-editing therapy delivers 'unprecedented' results | SCAI fights for interventional cardiologists | AI for STEMI detection

First-in-human data suggest the therapy, CTX310, could be a breakthrough for patients with lipid disorders.

SCAI President Srihari Naidu, MD, detailed some of the challenges interventional cardiologists face as reimbursements keep declining. The group has been building new partnerships with other medical societies to strengthen its influence in Washington. 

Researchers put an advanced AI model to the test, using it to evaluate the ECG results of more than 1,000 patients. It performed quite well. 

The new drug from Merck was linked to several benefits for patients who are already on statins. If an oral PCSK9 inhibitor gains FDA approval, it could be a game-changer for the field of preventive medicine. 

Sahil Parikh, MD, said it was clear at TCT 2025 that the specialty is getting more and more involved with endovascular procedures for stroke, pulmonary embolism and peripheral artery disease.

GenesisX represents the company’s most accessible robotic system to date. It requires no room shielding or structural anchoring, for example, and the size has been significantly reduced.

Researchers tracked data from nearly 8,000 patients evaluated with Heartflow's FDA-cleared Plaque Analysis software. Overall, the technology's Plaque Staging feature was found to provide significant value during the diagnosis and management of these patients.

Robert H. Bartlett, MD, was a pioneer surgeon who helped develop the world's first ECMO technology. He died at the age of 86 following a long illness. 

This decision expands access to renal denervation to many more patients throughout the United States. Recor Medical and Medtronic both gained FDA approval for their RDN systems in 2023, and other vendors are actively developing their own treatment options.

Intellia Therapeutics paused clinical trials for ATTR-CM and ATTR-PN after a patient was hospitalized due to a significant liver injury. 

Shockwave Medical and FastWave Medical have shared new first-in-human data on their advanced IVL offerings. Both companies are focused on addressing difficult-to-cross lesions that often cause problems for cardiologists.